The distinction of malignant mesothelioma from reactive mesothelial proliferation remains to be a major challenge for surgical pathologists. In this study, we investigated whether insulin-like growth factor II messenger ribonucleic acid-binding protein 3 (IMP3), an oncofetal protein, can be used as a biomarker to distinguish between malignant and reactive mesothelial cells. A total of 109 cases (mesothelioma, n = 45; reactive mesothelial proliferation, n = 64) were examined by immunohistochemistry for IMP3 expression. IMP3 showed strong cytoplasmic staining in 33 of 45 (73%) mesothelioma cases. In contrast, the expression of IMP3 was undetectable in all (64 cases) benign reactive mesothelial proliferations. Among the IMP3-positive mesotheliomas, 27 (82%) exhibited diffuse IMP3 expression. The vast majority of IMP3-positive subtypes of mesotheliomas showed IMP3 expression in >50% of malignant cells, as this diffuse staining pattern occurred in 17 (81%) cases of epithelial, 4 (100%) cases of sarcomatoid, and 6 (75%) cases of mixed types of mesothelioma. In addition, 2 cases, which were initially diagnosed as atypical mesothelial proliferations and later confirmed to be mesotheliomas, showed diffuse IMP3 expression. Our findings suggest that IMP3 is a new positive biomarker for malignant mesothelioma. IMP3 immunohistochemical staining can be used as an adjunct tool in the distinction of malignant mesothelioma from reactive mesothelial proliferations.
M alignant mesothelioma is an aggressive tumor with a median survival of 12 months from the time of diagnosis. 25 The incidence of malignant mesothelioma is increasing and is projected to continue to increase for the next 10 to 20 years worldwide. 1, 15, 22, 24 Distinguishing malignant mesothelioma from benign reactive mesothelial proliferations remains to be a challenge for surgical pathologists. The histologic features of reactive mesothelial proliferation include high cellularity, numerous mitotic figures, and cytologic atypia, which mimic malignant mesothelioma. The key feature in distinguishing these 2 entities is stromal or adipose tissue invasion. However, entrapment of mesothelial cells within fibrous tissue or minimal invasion by malignant mesothelioma into only a few layers of collagenous tissue makes the distinction between these 2 entities even more difficult.
For the past 2 decades, investigators have tried to identify biomarkers, which will distinguish malignant mesothelioma from reactive mesothelial proliferation. [2] [3] [4] 11, 13, 14, 23, 31 However, these biomarkers are rarely used in the clinical setting due to their low sensitivity and specificity. Kato et al 12 have reported the detection of glucose transporter isoform-1 in 48 of 48 cases of malignant mesotheliomas and none of 40 cases of reactive mesothelial proliferations. However, the high sensitivity and specificity reported could not be confirmed by other groups. 7 Takeda et al 28 demonstrated utilization of 9p21 homozygous deletion by fluorescence in situ hybridization in discriminating malignant mesothelioma from reactive mesothelial proliferation. In cytologic specimens but not in paraffin-embedded tissues, Sato et al 26 reported that CD146 was a sensitive and specific marker for mesotheliomas.
IMP3 is an oncofetal protein involved in embryogenesis, and its expression is associated with a number of malignant neoplasms. 6, [8] [9] [10] [17] [18] [19] [20] 27, 33, 35 Our previous studies have shown that IMP3 is an important cancer-specific protein that is associated with aggressive and advanced cancers, and is specifically expressed in malignant tumors but is not found in benign tissues. 6, [8] [9] [10] 17, 35 Moreover, it has been shown that IMP3 promotes tumor cell proliferation, invasion, and metastasis. 16, 29 Recently, Findeis-Hosey and Xu 5 have suggested that IMP3 may play an important role in the diagnosis of malignant mesothelioma.
In this study, we examined IMP3 expression in malignant mesothelioma and reactive mesothelial proliferations to determine whether IMP3 can serve as a biomarker to distinguish these 2 entities.
MATERIALS AND METHODS

Cases
A total of 109 cases (Table 1) , 45 malignant mesotheliomas (pleuropneumonectomy, n = 12; pleural biopsy, n = 26; peritoneal resection, n = 7) and 64 reactive mesothelial proliferations (pleuropneumonectomy, n = 13; pleural biopsy, n = 48; peritoneal resection, n = 3) were obtained from the formalin-fixed, paraffin-embedded block archives from the UMass Memorial Medical Center (n = 104) and the City of Hope National Medical Center (n = 5). Among the malignant mesothelioma cases, 27 were of the epithelioid type (60.0%), 10 were of the mixed type (22.2%), and 8 were of the sarcomatoid type (17.8%). All the cases were collected between January 1997 and April 2010, and the diagnoses were confirmed by at least 2 pathologists.
Immunohistochemical Analysis
Immunohistochemical studies were performed on 5-mm sections of formalin-fixed, paraffin-embedded tissue. Antigen retrieval was carried out with 0.01 mol/L citrate buffer at pH 6.0, in an 800-W microwave oven for 15 minutes before immunostaining. The slides were stained on a DAKO Autostainer (DAKO Corporation, Carpinteria, CA) using the EnVision (DAKO) staining reagents. The sections were first blocked for endogenous protein binding and peroxidase activity with an application of Dual Endogenous Block (DAKO) for 10 minutes, followed by a buffer wash. The sections were then incubated with a mouse monoclonal antibody specific for IMP3 (L523S, DAKO) at a 2.0 mg/mL concentration for 30 minutes. The sections were then incubated with the EnVision+ Dual Link reagent (a polymer conjugated with goat-anti-mouse-Ig and horseradish peroxidase) for 30 minutes and treated with diaminobenzidine and hydrogen peroxide to produce the visible brown pigment. The sections were counterstained with hematoxylin, dehydrated, and coverslipped with a permanent media.
Sections of lymphoid proliferations with known positivity of IMP3 were used as positive controls for IMP3 staining. Negative controls were performed by replacing the primary antibody with an isotype-specific IgG control.
Morphologic Evaluation
The diagnosis of malignant mesothelioma or reactive mesothelial proliferation was established by the examination of hematoxylin and eosin-stained sections by at least 2 pathologists. Positive staining of IMP3 was defined as a dark brown cytoplasmic staining pattern in >5% of the mesothelial/tumor cells, which was easily observed at low-power magnification (r Â 40). No staining, scant fine granular background staining of mesothelial/ tumor cells, which cannot be seen at low-power magnification (r Â 40), or scattered focal staining with IMP3 positivity in <5% of total cells was considered to be negative. The status of IMP3 was assessed by 2 researchers (M.S. and Z.J.) without knowledge of the clinical and pathologic features of the cases.
RESULTS
Positive IMP3 staining was detected in 33 of 45 (73%) malignant mesotheliomas, which highlighted clusters of malignant mesothelial cells ( Table 2 ). Positive IMP3 expression was manifested as a dark brown cytoplasmic staining pattern ( Fig. 1 ). Of the 33 malignant mesotheliomas with IMP3 expression, 27 (82%) cases showed diffuse IMP3 expression in >50% of malignant cells, whereas only 6 (18%) cases showed IMP3 expression in <50% of malignant cells [2 (6%) cases with IMP3 expression in 25% to 50% of cells, and 4 (12%) cases with IMP3 expression in 5% to 25% of malignant cells]. IMP3 expression was found in all subtypes of malignant mesotheliomas (Fig. 1 ) including 21 of 27 (78%) epithelioid, 8 of 10 (80%) mixed, and 4 of 8 (50%) sarcomatoid mesotheliomas. Importantly, the majority of IMP3-positive subtypes of mesotheliomas showed IMP3 expression in >50% of malignant cells, as this diffuse staining pattern occurred in 17 (81%) cases of epithelioid, 4 (100%) cases of sarcomatoid, and 6 (75%) cases of mixed types of mesothelioma ( Table 3 , Fig. 1 ).
Among a total of 45 cases of malignant mesothelioma, 38 cases were from the pleura and 7 cases were from the peritoneum. IMP3 staining was detected in 27 (71%) cases of pleural malignant mesothelioma, with 23 (85%) of these cases showing diffuse IMP3 expression in >50% of malignant cells. Six (86%) cases of peritoneal malignant mesothelioma exhibited IMP3 expression, with 4 (67%) of these cases displaying diffuse IMP3 expression in >50% of malignant cells.
In contrast, there was no IMP3 expression in the 62 cases of reactive mesothelial proliferations ( Table 2 , Fig. 1) . Surprisingly, 2 cases initially diagnosed as "atypical mesothelial proliferation" had been sent out for an expert's second opinion. The expert's diagnoses were "atypical mesothelial cell proliferation" in one case and "malignant mesothelioma" in the other case. Both cases showed strong and diffuse IMP3 expressions, and both patients died from mesothelioma soon after the patho logic diagnoses were made.
DISCUSSION
Providing an accurate diagnosis between malignant mesothelioma and reactive mesothelial cell proliferation is clinically important. Malignant mesothelioma requires aggressive treatment and has a high level of morbidity. In contrast, a reactive mesothelial proliferation is a selflimited disease.
In this study, we analyzed the pattern of IMP3 expression in a large number of malignant mesotheliomas and reactive mesothelial cell proliferations. Our data show that IMP3 is a sensitive and specific marker for malignant mesotheliomas, regardless of the subtype and location. Therefore, IMP3 expression in atypical mesothelial cell proliferation may increase the level of confidence in establishing a definitive diagnosis of malignancy. Furthermore, 2 cases FIGURE 1. Malignant mesotheliomas [epithelioid (first row), sarcomatoid (second row), and mixed type (third row)] showed diffuse, dark brown, cytoplasmic IMP3 staining. However, no IMP3 expression was detected in reactive mesothelial proliferation (fourth row).
that were thought to represent atypical mesothelial proliferations were strongly positive for IMP3 and were clinically diagnosed as malignant mesothelioma. Subsequently, both patients expired secondary to mesothelioma. These results indicate that when used in conjunction with histologic criteria, IMP3 staining can be a useful adjunct in distinguishing malignant mesothelioma from reactive mesothelial cell proliferations.
The abnormal expression of IMP3 in mesotheliomas but not in reactive mesothelial proliferation raises the possibility that IMP3 may play a role in the pathogenesis of mesothelioma. IMP3 is a member of the IMP family, which plays an important role in RNA localization and stabilization, as well as in cell growth and migration during the early stages of embryogenesis. IMP3 is a fetal protein that is expressed in embryonic tissues, whereas its expression level is undetectable in adult tissues. [18] [19] [20] 32 IMP3 is also an oncoprotein, and its overexpression has been found in a variety of tumors, including cancer of the pancreas, lung, stomach, colon, kidney, endocervix, endometrium, esophagus, and soft tissue sarcomas. However, IMP3 expression is not detected in adjacent benign tissues. 17, 18, 21, 30, [33] [34] [35] In vivo data have demonstrated that IMP3 plays a very important role in cell proliferation and invasion. 16, 29 In addition, IMP3 was found to regulate the expression of CD24, CD44, cell adhesion molecules (ALCAM, SynCAM, MCAM), and matrix metalloproteinase 1, all of which are associated with cell adhesion and tumor invasion. 29 Clinical studies have demonstrated that aberrant IMP3 expression in tumor cells was associated with aggressive clinical behavior. Our previous studies have also demonstrated that IMP3 expression is associated with aggressive tumor behavior in renal cell carcinoma and urothelial carcinoma. [8] [9] [10] 27 Therefore, it is possible that IMP3 is also involved in the pathogenesis and the aggressive behavior of malignant mesothelioma.
Although our findings suggest that IMP3 is an excellent biomarker for diagnosis of mesothelioma, caution should be exercised in interpreting IMP3 immunohistochemical results. IMP3 expression was found in 33 of 45 malignant mesotheliomas, and therefore is not 100% sensitive for mesothelioma. Negative IMP3 staining in suspicious cases does not necessarily render a benign diagnosis. Adequate routine histologic evaluation is still a crucial step to establish a malignant diagnosis in the mesothelial lesions.
In summary, our study shows that most malignant mesotheliomas are positive for IMP3, whereas all reactive mesothelial proliferations are negative for IMP3. The expression of IMP3 can increase the level of confidence in establishing the diagnosis of malignant mesotheliomas. IMP3 is a good diagnostic biomarker for distinguishing mesotheliomas from reactive mesothelial proliferations in formalin-fixed, paraffin-embedded tissue sections. 
